Technology & Pipeline

Preclinical antibody pipeline & partnering opportunity

Program Format MOA Indication Partner Discovery Preclinical Phase I
IBI302 Bi-functional Anti-angiogenesis AMD Innovent Biologics
(WW)
 
AP201 Bi-specific Dual Immunomodulation TNBC, HNSCC, OVARIAN Tasly Biopharma
(China)
 
AP505 Bi-specific Targeted Immunomodulation LUNG, HCC Tasly Biopharma
(China)
 
AP116 lgG T/NK Activation NHL, NSCLC Tasly Biopharma
(China)
 
AP120 lgG DC Activation SOLID TUMORS --
 
AP203 Bi-specific Target-dependent Immunomodulation SOLID TUMORS --